Radioresistance remains a major challenge in the treatment of glioblastoma multiforme (GBM). Recent data strongly suggests the important role of miRNAs in cancer progression and therapeutic response. Here, we have established a radioresistant human GBM cell line U87R derived from parental U87 and found miR-135b expression was upregulated in U87R cells. miR-135b knockdown reversed radioresistance of U87R cells, and miR-135b overexpression enhanced radioresistance of U87 cells. Mechanically, bioinformatics analysis combined with experimental analysis demonstrated GSK3b (Glycogen synthase kinase 3 beta) was a novel direct target of miR-135b. Moreover, GSK3b protein expression was downregulated in U87R cells and restored expression of GSK3b increased radiosensitivity of U87R cells. In addition, clinical data indicated that the expression of miR-135b or GSK3b was significantly association with IR resistance of GBM samples. Our findings suggest miR-135b is involved in the radioresistance of human GBM cells and miR-135b-GSK3b axis may be a novel candidate for developing rational therapeutic strategies for human GBM treatment.
Introduction
Gliomas are the most common type of primary brain tumors in adults and persist as serious clinical and scientific problems [1] . Survival depends heavily on the histological grade of the tumor, but patients afflicted with the most malignant glioma, glioblastoma multiforme (GBM). survive on average about 15 months. Despite advances in current multi-modal treatment options, the overall prognosis of patients with GBM remains dismal [2] . These include rapidness and invasiveness of tumor growth, the genetic heterogeneity of the tumors, and our poor understanding of the molecular mechanisms governing disease manifestation and progression [3, 4] . Ionizing radiation (IR) plays a major role in the treatment of patients with GBM. Factually, the efficacy of this therapeutic modality is often limited by the occurrence of radioresistance [5] . However, the molecular mechanisms responsible for the radioresistance of human GBM are still not clear yet.
Recently, it has been recognized that a class of endogenous, small, non-protein coding single-stranded RNA molecules, termed microRNA (miRNA), plays a crucial role in the post-transcriptional regulation of gene expression. More and more reports have demonstrated that miRNAs are aberrantly expressed in many human cancers, functions as oncogenes and tumor suppressors [6] .
Some miRNAs have been demonstrated perhaps to play key roles in tumorigenesis, progression, invasion or metastasis in human GBM, such as miR-181, miR-200b, miR-182, miR-381, miR-142-3p and others [4, [7] [8] [9] . However, the role of miRNAs in radioresistance of human GBM largely remains unknown. In the present study, compared to its parental cell line U87, we show miR-135b is upregulated in radioresistant human GBM cell line U87R, which targets Glycogen synthase kinase 3 beta (GSK3b). Our findings suggest that miR-135b and GSK3b are potential biomarkers to estimate the sensitivity of human GBM to radiotherapy and help to developing rational therapeutic strategies.
Materials and Methods

Tissue specimens
We obtained frozen tissue samples of 30 human GBM tissues and 30 normal brain (NB) tissues from the Xiangya Hospital of the Central South University, Hunan, China between March 2008 and November 2010. The study was approved by the Ethical Committee of the Faculty of Medicine, the Central South University, and written informed consent was obtained from every subject. The collection and use of tissues followed the procedures that are in accordance with the ethical standards as formulated in the Helsinki. Tumor samples were diagnosed by 2 pathologists who were blinded to patient data using the World Health Organization (WHO) system. Clinical data, including gender, age, follow-up, and outcome, were obtained from the medical records.
Cell culture
Human GBM cell line U87 and its radioresistant derivate cell line U87R were cultured in DMEM (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies) in a humidified cell incubator with an atmosphere of CO2 at 37uC. Exponentially growing cells were used for experiments.
Survival foci formation assay
Cells in exponential growth phase were plated into a six-well plate at 2000 cells/well and treated with a range of radiation doses (0, 2 and 4 Gy) after adhesion. When most cell clones had reached .50 cells, they were stained with 0.06% crystal violet, and foci number was counted.
Cell proliferation assay
Cell proliferation was monitored by the MTS assay using the CellTiter96AQueous One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions. Cells were seeded into 96-well plates at 2000 cells/well (0.20 ml/well), and irradiated with 2 Gy or not. The cell proliferation assay was performed on days 0, 1, 2, 3 and 4 by incubation with MTS (0.02 ml/well). After 2 h further incubation, the absorbance at 490 nm of each well was recorded on the BiotexELX800 and the absorbance represented the cell number.
Quantitative RT-PCR analysis (qRT-PCR)
Total RNAs were extracted from cells with TRIzol reagent (Invitrogen). For the detection of GSK3b mRNA, cDNA was synthesized from 1 mg of total RNA by means of the reverse reaction kit according, which was used in accordance with the manufacturer's instructions (Promega). Human GAPDH was amplified in parallel as an internal control. The primers were: GAPDH was used as an internal control and the qRT-PCR was repeated three times. The primers for GAPDH were: forward primer 59-ATTCCATGG-CACCGTCAAGGCTGA-39, reverse primer 59-TTCTCCAT-GGTGGTGAAGACGCCA-39; for GSK3b were: forward primer 59-GACTAAGGTCTTCCGACCCC-39, reverse primer 59-TTAGCATCTGACGCTGCTGT-39.
CellsTransfection miR-135b mimics, miR-135b inhibitor and relative controls were purchased from Ambion. Cells were trypsinised, counted and seeded onto 6-well plates the day before transfection to ensure 70% cell confluence on the day of transfection. The transfection of mimics, inhibitor, pLV-GFP-GSK3b vector and related controls was carried out using Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's procedure. The mimics, inhibitor and controls were used at a final concentration of 100 nM. At 48 h post-transfection, follow-up experiments were performed. 
Construction of luc-UTR vectors
The full-length GSK3b 39-UTR was cloned into the EcoRI and HindIII sites of the pMIR-REPORT luciferase vector (Ambion, Austin, TX, U.S.) using PCR generated fragment. A Luc-mut vector in which the first seven nucleotides complementary to the miR-135b seed-region were mutated by site-directed mutagenesis (Stratagene) served as a mutant control.
Luciferase assay
Luc-wt, Luc-mut, and Luc-ctrl were co-transfected within vitroproduced miR-135b into U87 cells. The pMIR-REPORT bgalactosidase control vector was transfected and served as a control. Luciferase activity was measured in cell lysates 48 h after transfection using a dual-light luminescent reporter gene assay kit (Applied Biosystems).Results were normalized against b-galactosidase activity.
Western blot
Cell protein lysates, cytosol protein or nuclear protein was separated in 10% SDS-polyacrylamide gels, electrophoretically transferred to polyvinylidene difluoride membranes (Millipore), then detected with mouse monoclonal antibody for RAB21 (sc-81917), mouse monoclonal antibody for GSK3b and LZTS1 (Santa Cruz), mouse monoclonal antibody for b-actin (Abcam) and commercial ECL kit (Pierce). The intensity of protein fragments was quantified using ChemicalDocTM XRS+ (Bio-Rad).
Immunofluorescence assay
For immunofluorescence assay cells were seeded on coverslips, fixed with 3% paraformaldehyde for 20 min and then permeabilized with 0.1% Triton X-100. Cells were incubated with antibodies against GSK3b for 2 hours at room temperature. Then, cells were incubated with species-specific Alexa488-conjugated secondary antibodies (1:2000; Invitrogen) for 1 h at room temperature. Nuclei were counterstained with 49,6-diamidino-2-phenylindole (DAPI, 1 mg/mL).
Statistical analysis
Quantitative results were expressed as the mean 6 standard deviation. Statistical analysis was carried out with Statistical Package for Social Science (SPSS for Windows Version 16.0. USA). Student t-test was used to evaluate the statistical significance. A p value ,0.05 or 0.01 was set as the criteria for statistical significance.
Results
Biological characteristics of U87R cells
In order to explore the mechanism responsible for radioresistance in human GBM, firstly, we established aradioresistant human GBM cell line. To generate a radioresistant human GBM cell line U87R, we exposed U87 cells to a range of doses of radiation (1, 2, 4, 6 and 8 Gy) over a period of 12 months [10, 11] . Cells were lonizing radiation (IR) at least three times at each dose and cells did not receive next radiation until they got an 80% confluence after each radiation. To verify the radioresistant phenotype, we radiated U87 and U87R cells and examined them by survival foci formation assay. U87 and U87R cells were irradiated with 0, 3 and 6 Gy and examined by survival foci formation assay. Compared to U87, U87R showed no change of foci formation ability when radiation was absent, but gained more foci formation and higher survival fractions when exposed to radiation ( Figure 1A-C) . The effect of radiation on cell growth was also examined by subjecting U87 and U87R cells to 3 Gy IR. As shown in Figure 1D , the U87R cell line had more cell numbers than U87 after radiation. So that, U87R cells is more radioresistant than parental U87 cells.
miR-135b enhances radioresistance of U87 cells
Using miRNA specific RT-qPCR, we found miR-135b expression was about 5.17 fold higher in U87R cells than that in U87 cells (Figure 2A ). To investigate whether miR-135b has a direct function in modulating the radioresistance in U87 cells, we used loss-of-function and gain-of-function approaches in U87R and U87 cells, respectively. So we inhibited miR-135b function with miR-135b specific inhibitor in U87R cells to further characterize its biological function ( Figure 2B ). qRT-PCR and Western blot [12] analysis showed that the transfection was successful ( Figure S1 ). miR-135b inhibition significantly increased the radiosensitivity of U87R cells measured by survival foci formation assay ( Figure S2 and Figure 2D-E) . Conversely, the ectopic expression of miR-135b in U87 cells was achieved by miR135b mimics transfection ( Figure 2C ). Overexpression of miR135b with mimics in U87 cells efficiently increased the radioresistance measured by survival foci formation assay ( Figure 2F-G) . 
miR-135b directly targets GSK3b
To analyze the molecular mechanisms of miR-135b involvement in radioresistance of human GBM cells, online softwares TargetScan was used to search for potential miR-135b target genes. A predict potential target of miR-135b, and GSK3b with critically conserved binding site was selected for further molecular and functional confirmation ( Figure 3A) . To investigate the corelation between miR-135b and GSK3b, the expression of GSK3b at mRNA and protein levels were detected in U87 and U87R cells. The expression of GSK3b and mRNA protein in U87R cells was much lower than that in U87 cells (Figure 3B, C) . Moreover, GSK3b protein level in U87R cells significantly increased after miR-135b inhibitor transfection. Conversely, GSK3b protein level in U87 cells decreased after miR-135b mimics transfection ( Figure 3D, E) . To assess whether GSK3b is a direct target of miR-135b, we subcloned the full-length 39-UTR of GSK3b into the luciferase reporter vector. It's shown that addition of in vitro-produced miR-135b suppressed the luciferase activity of the 39-UTR of GSK3b upon co-transfection of the luciferase vector (wild-type, mutant) with the in vitro-produced microRNAs (miR-135b mimic or scramble control) into U87 cells and vitroproduced microRNAs (miR-135b inhibitor or scramble control) into U87R cells ( Figure 3F ). This inhibition was abolished when the seed sequences of the miR-135b were mutated in the Luc-mut vector. These results strongly demonstrated the specificity of miR-135 targeting GSK3b.
GSK3b overexpression reverses the radio-resistance of U87R cells
GSK3b is a direct target of miR-135b in U87R cells. To investigate the role of GSK3b in human GBM radiosensitivity, GSK3b overexpression with pLV-GFP-GSK3b vector was applied. pLV-GFP-GSK3b vector transfection significantly increased GSK3b protein level ( Figure 4A ). Then, we observed the functional effect of restored GSK3b expression on radiosensitivity and found GSK3b overexpression significantly reversed radioresistance of U87R cells detected by survival foci formation assay ( Figure 4B-C) .
The association of miR-135b or GSK3b expression with IR resistance is clinically relevant
To determine whether the association of miR-135b or GSK3b expression with IR resistance is clinically relevant, we examined the expression levels of miR-135b or GSK3b in a cohort of 30 GBM tissues and 30 normal brain tissues using qRT-PCR (miR135b and GSK3b) and immunohistochemistry (GSK3b) assays. Our result showed that GSK3b protein in approximate 83.3% (25/30) samples was positive among the 30 normal brain tissues. However there was approximately 13.3% (4/30) positivity in 30 GBM tissues. The representative images are in Figure 5A . GSK3b mRNA was found to be significantly downregulated in these GBM specimens compared with normal brain tissues (p,0.01, Figure 5B) . But miR-135b was found to be significantly upregulated in these GBM specimens compared with normal brain tissues (p, 0.01, Figure 5C ). The correlation analysis showed that the expression of miR-135b was negatively correlated with the expression of GSK3b proteins in normal brain and GBM tissues (p = 0.07, Figure 5D ). Furthermore, we examined the miR-135b or mRNA expression of GSK3b in tumor tissues from patients who received IR treatment. miR-135b or GSK3b was measured in ten pairs of frozen GBM specimens, including primary tumors and the corresponding recurrent tumors. qRT-PCR data showed that miR-135b was dramatically elevated in the recurrent tumors compared to the primary tumors after IR treatment, but the mRNA expression of GSK3b was dramatically declined in the recurrent tumors compared to the primary tumors after IR treatment (p,0.01, Figure 5E , F), indicating that the glioma cells with high expression of miR-135b or GSK3b were more resistant to the IR and more susceptible to death, whereas the glioma cells with low miR-135b or GSK3b levels were more sensitive to IR. Together, these results suggest that miR-135b or GSK3b is of clinical significance as a mediator of IR resistance.
Discussion
Intrinsic and acquired resistance of therapeutic-resistance including chemoresistance and radioresistance is the major clinical obstacle in cancer treatment. Although mechanisms for therapeutic-resistance have been extensively investigated using established chemo-or-radio-resistant cell models [11, 13, 14] , but they are still [6, 15] . MicroRNAs also modulate responses to anti-cancer therapy. In the context of radiation oncology microRNAs were found to modulate cell death and proliferation after irradiation [11] . For example, miR-1285 was observed in the present study might possibly lead to increased radioresistance in subsequent radiotherapy sessions. Furthermore, irradiation-induced changes in microRNA expression levels might also affect migration and metastasis of surviving cells [11] . IRinduced over-expression of miR-151-5p might enhance dissemination and migration of malignant cells during a course of radiation therapy, since miR-151-5p was found to increase migration and intra-hepatic metastasis in hepatocellular carcinoma [16] . Another candidate for regulating responsiveness to anticancer therapy is the let-7 family, although certain members of the let-7 family had different effects on radiation sensitivity in A549 lung cancer cells [17] . let-7a overexpression was shown to increase radiation sensitivity in lung cancer cells [18] .
In regard to human GBM, ionizing radiation (IR) is a key component of standard therapy for GBM patients. However, acquired resistance limits the therapeutic efficacy of IR [5] . Therefore, the identification of targets responsible for IR resistance is critical for successful GBM treatment. In this study, we show, for the first time, that miR-135b functions as a novel mediator of IR resistance in glioma cells. In order to explore the miR-135b-GSK3b Axis May Be a Novel Therapeutic Strategy for GBM PLOS ONE | www.plosone.orgmechanisms responsible for radioresistance of human GBM, we established a radioresistant human GBM cell line U87R and found miR-135b was upregulated in U87R cells. Expectedly, miR135b knockdown significantly increased the radiosensitivity of U87R cells. However, miR-135b overexpression obviously enhanced the radioresistance of U87 cells. Previous evidence has indicated that miR-135b is overexpressed in lung [12] , colon [19, 20] , breast [21] and prostate [22] cancers, which strongly suggests a general role in different types of cancers. The ability of miR-135b to target multiple tumour suppressors indicates an indiscriminate ability to promote tumour progression and metastasis. Other researchers have found that miR-135b may also contribute to mediate NPM-ALKassociated oncogenicity in largecell lymphomas [23] . A miR-135b antagomir (Antago-135), which is able to functionally suppress miR-135b, effectively reduced metastasis and tumour burden, which suggests the potential for the development of miR-135b antagonists for lung cancer therapy [12] . Here, we firstly demonstrate miR-135b is involved in the radioresistance in human GBM cells.
As the mechanism responsible of miR-135b in human GBM cells, we found miR-135b directly targets GSK3b whose mRNA and protein expression is downregulated in U87R cells with endogenous upregulation of miR-135b expression. GSK3b is a serine/threonine protein kinase involved in glycogen metabolism and the Wnt signaling pathway, which plays important roles in embryonic development pathway and tumourigenesis. Active GSK3b is able to phosphorylate substrates, such as b-catenin and Tau, resulting in ubiquitin-mediated degradation [24] . Wnt signaling inactivates GSK3b through the phosphorylation of Ser9 residue and prevents it from phosphorylating b-catenin, thus stabilizing GSK3b in the cytoplasm [25] . miR-135b has also been reported to induce Wnt signaling pathway by the suppression of APC in colorectal cancers [26] and lung cancer [12] . Studies have shown clear regulatory mechanisms of GSK3b activity in various cancer, however, that of GSK3b expression remains unclear in GBM. Here, we demonstrated miR-135b could direct suppress GSK3b expression at mRNA and protein level in human GBM cells. In addition, we examined the expression levels of miR-135b and GSK3b in human GBM specimens and found that miR-135b was significantly upregulated in primary GBM tissues. On the contrary, GSK3b was significantly downregulated in primary GBM tissues. More importantly, we found that elevated expression of miR-135b and GSK3b are associated with recurrent GBM patients who underwent IR therapy. To the best of our knowledge, we will explore the detailed mechanism responsible for miR-135b-GSK3b axis in modulating radiosensitivity in human GBM cells.
In conclusion, the U87R and U87 cell lines are useful models for clarifying the radioresistant mechanisms in human GBM. miR135b is upregulated in U87R cells and contributes radioresistance in U87 cells. As for mechanism, we found GSK3b is a direct target of miR-135b, and ectopic GSK3b expression significantly reverses radioresistance in U87R cells. Thus, our findings suggest miR135b-GSK3b axis will be valuable biomarkers for the radiosensitivity and related interference will be worthy therapeutic strategies for human GBM patients. Author Contributions
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